ProMIS Neurosciences (NASDAQ:PMN) Trading Up 1.5%

ProMIS Neurosciences, Inc. (NASDAQ:PMN)’s stock price shot up 1.5% during mid-day trading on Friday . The company traded as high as $1.98 and last traded at $1.98. 1,032 shares were traded during trading, a decline of 97% from the average session volume of 37,766 shares. The stock had previously closed at $1.95.

ProMIS Neurosciences Stock Up 1.5 %

The company has a market cap of $37.54 million, a P/E ratio of -1.75 and a beta of 0.67. The business has a fifty day moving average price of $2.04 and a 200-day moving average price of $1.78.

ProMIS Neurosciences (NASDAQ:PMN) last issued its quarterly earnings data on Monday, April 1st. The company reported ($0.09) earnings per share (EPS) for the quarter. As a group, research analysts expect that ProMIS Neurosciences, Inc. will post -1.11 earnings per share for the current year.

Institutional Investors Weigh In On ProMIS Neurosciences

An institutional investor recently bought a new position in ProMIS Neurosciences stock. Affinity Asset Advisors LLC purchased a new stake in ProMIS Neurosciences, Inc. (NASDAQ:PMN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 265,958 shares of the company’s stock, valued at approximately $527,000. Affinity Asset Advisors LLC owned approximately 3.10% of ProMIS Neurosciences at the end of the most recent quarter. 50.13% of the stock is currently owned by hedge funds and other institutional investors.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.